Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.

Detailed results from the phase 3 EVOKE and EVOKE+ trials of the oral GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) in early Alzheimer’s disease (AD) have been presented. The initial negative topline results announced last week by the company were met with disappointment in the AD research community, but the newly presented biomarker data offer some grounds for optimism and may point to a potential path forward.

For first-generation college student Bianca Balderas, even a small increase in tuition could force her to drop out of the College of Southern Nevada. Students like Balderas came to the Board of Regents meeting Friday to voice their concerns about a proposal to raise tuition and fees at institutions in the Nevada Higher System of Education.

Regardless of their business or educational backgrounds, federal prohibition and the erratic patchwork of state laws mean many cannabis operators and investors across the industry have become by default experts in arcane points of law.

New research is revealing people who have cosmetic filler injections in their face are at possible risk for dangerous complications involving blocked arteries.

Two years after a gunman killed three UNLV professors and seriously injured another, the college says it has plans to construct a healing garden that memorializes the tragedy.

UNLV will not be adding a Vegas Loop station to their campus. Interim university president Chris Heavey said the university looked at the pros and cons and decided to pass on The Boring Company's offer to build a station out for them for free.

No one would have expected back in 1985 that the National Finals Rodeo would be the massive success that it has become. But now, 40 years later, it’s one of the toughest tickets to get, and what is considered the Super Bowl of rodeos is primed to extend its record of 379 consecutive sell-out performances with 10 nights of competition Thursday through Dec. 13 at UNLV’s Thomas & Mack Center.